Sector News

Acquisitive Quotient buys CDMO Pharmaterials, reveals new identity

November 15, 2017
Life sciences

After two U.S. acquisitions back in February, Quotient Clinical has been renamed as Quotient Sciences, and right after that, made another purchase.

U.K.-based CDMO Pharmaterials is now part of the rebranded Quotient Sciences. Quotient said in a release that the acquisition strengthens its formulation and manufacturing services footprint in its home country.

Services offered at Pharmaterials fall within Quotient’s existing portfolio, including characterization and optimization of small-molecule drug physical forms, the development of preclinical and clinical formulations, as well as contract manufacturing for clinical use and commercial supply.

Founded in 2000, Pharmaterials has established 13 GMP manufacturing suites in a 48,000-square-feet facility, which also has more space for future expansion.

Quotient entered the U.S. market through two closely announced acquisitions in February—clinical pharmacology expert Seaview and Charles River Laboratories’ CDMO unit QS Pharma.

“Quotient’s overall strategy behind the acquisitions over the last 12 months is to replicate our Translational Pharmaceutics platform in the USA,” Quotient spokesperson Robin Bodicoat told FierceCRO.

The platform works by combining services from traditional CDMOs with those from CROs, namely integrating formulation development and early-stage clinical research with GMP manufacturing. The company said the approach is proven to reduce drug development costs and shorten timelines.

After these acquisitions, Quotient now has 700 employees working at five sites in the U.S. and the U.K.

By Angus Liu

Source: Fierce Biotech

comments closed

Related News

November 19, 2022

Sequana announces results from study of direct sodium removal

Life sciences

Sequana, a company focusing on liver disease, heart failure and cancer has announced positive top-line results from SAHARA – the phase 2a study using its first-generation direct sodium removal (DSR) product, DSR 1.0. Data from ten evaluable diuretic-resistant heart failure patients confirmed long-lasting clinical benefits.

November 19, 2022

Bristol Myers Squibb opens 125-acre biologics campus in Dublin

Life sciences

Bristol Myers Squibb has officially opened its Cruiserath Biologics site in Dublin. The site, which represents a $1bn investment – was officially opened by the company’s chief executive officer, Giovanni Caforio, who arrived from New York, and site general manager Pádraig Keane.

November 19, 2022

Pharma must stay the course on Twitter as docs are not abandoning the platform yet: Report

Life sciences

Like it or loathe it, and whatever its new direction, Twitter is still a powerful platform for doctors, and pharma should not abandon the troubled social media site yet, according to a new report from healthcare consultants at ZoomRx.